Bausch + Lomb and Novaliq win approval for dry eye disease treatment
Bausch + Lomb and Novaliq secured an approval for their dry eye disease drop on Thursday, to be marketed as Miebo.
The drug, also known as perfluorohexyloctane ophthalmic solution or previously NOV03, targets tear evaporation, a leading cause of dry eye disease. Bausch + Lomb CEO Brent Saunders expects the drug to be available in the second half of this year.
“Today’s FDA decision marks a tremendous milestone for Bausch + Lomb as MIEBO becomes our first prescription pharmaceutical eye treatment to be approved by the FDA since becoming an independent, publicly traded eye health company,” Andrew Stewart, president of ophthalmic pharmaceuticals, said in a news release.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters